Quantcast

Latest Low-density lipoprotein Stories

2014-08-31 04:21:07

Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS, Aug. 31, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.(...

2014-08-31 04:20:55

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y., Aug. 31, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia....

2014-08-28 08:28:39

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) study evaluating evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol met its co-primary endpoints: the percent...

2014-08-28 08:28:27

Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to...

Fenofibrate for diabetic women
2014-08-21 03:00:45

Dan Gafney, University of Sydney The cholesterol-lowering drug fenofibrate cuts cardiovascular disease risks by 30 percent in women with type-2 diabetes, a new University of Sydney study reveals. "The finding is good news for women," says the study's chairman, University of Sydney Professor, Tony Keech. "The study shows that fenofibrate reduced the risk of dying from cardiovascular disease, or having a stroke or other adverse cardiovascular event by 30 percent in women and 13 percent...

statins
2014-08-17 02:00:52

Traci Klein, Mayo Clinic A Mayo Clinic task force challenges some recommendations in the updated guideline for cholesterol treatment unveiled by the American College of Cardiology (ACC) and American Heart Association (AHA) in 2013. The task force concludes, based on current evidence, that not all patients encouraged to take cholesterol-lowering medications, such as statins, may benefit from them and that the guideline missed some important conditions that might benefit from medication....

2014-08-12 23:10:34

A Rise In Lipitor Lawsuit Claims Jumped In Five Months With Filings That Contend Development Of Type 2 Diabetes After Taking The Cholesterol Lowing Medication, Notes Wright & Schulte LLC Columbus, OH (PRWEB) August 12, 2014 The harmful drug attorneys at Wright & Schulte LLC have learned through a Reuters analysis that Lipitor diabetes lawsuits filed against Pfizer Inc. have spiked over the past five months primarily due to all federally filed Lipitor lawsuit claims consolidated in...

2014-08-12 12:29:20

LONDON, Aug. 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Hypercholesterolemia Market 2014-2018https://www.reportbuyer.com/product/2183843/Global-Hypercholesterolemia-Market-2014-2018.html About HypercholesterolemiaHypercholesterolemia is defined as a condition characterized by abnormally high levels of total cholesterol and LDL cholesterol in the blood. High cholesterol levels, in turn, can lead to cardiovascular diseases such as...

2014-07-30 08:33:01

Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo...

2014-07-30 08:32:55

- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y., July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related